SummaryThe aim of the study is to analyse the prevalence of cardiorenal metabolic diseases (CRM) such as chronic kidney disease (CKD), cardiovascular diseases (CVD), type-2 diabetes mellitus (T2DM), obesity, metabolic-associated steatohepatitis (MASH), metabolic-associated liver disease (MASLD), and hypertension, its overlap and the extent of underdiagnosis. It is known that diseases like CKD or MASH are underdiagnosed, however the extent of underdiagnosis in general and by disease stage in particular is unknown. Furthermore, the progression of undiagnosed and/or untreated CKD is planned to be investigated (determined via eGFR/UACR). By comparing the laboratory values that can be used for diagnoses/risk or probability assessment of suffering from the disease, with the specific cardio-renal diseases self-reported by the study participants, the proportion of undiagnosed individuals per disease is to be determined. In addition, it is planned to analyse whether socioeconomic and/or ethnic background, lifestyle, and potential genetic factors influence the occurrence, diagnosis of CRM diseases. The following variable groups are to be investigated: • Laboratory data, accelerometric and anthropometric data: intended to be used to identify the presence (and severity) of a CRM disease and to assess the risk of suffering from such a disease. • Self-reported diagnoses and medication: intended to be used to: serve as a basis for identifying diagnoses and to describe the treatment of the diseases. • Socioeconomicethnic, family and ethic background: intended to be analyzed to investigate potential correlations with the occurrence, recognition, and treatment of CRM diseases. • Lifestyle and physical activity: intended to be used to evaluate their impact on CRM diseases and to differentiate between MASH (Metabolically Associated Steatotic Hepatitis) and ASH (Alcoholic Steatohepatitis).

Keywords-

InstitutionsBoehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim